EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors

Kaysia Ludford iD, Won Jin Ho iD, Jane V Thomas iD, Kanwal P S Raghav iD, Mariela Blum Murphy iD, Nicole D Fleming iD, Michael S Lee iD, Brandon G Smaglo, Y Nancy You iD, Matthew M Tillman, Carlos Kamiya-Matsuoka, Selvi Thirumurthi und 13 weitere

Journal of Clinical Oncology · 20.04.2023 · 41 (12) · 2181-2190

DOI: 10.1200/jco.22.01351 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.04.2023. Verfasst von Kaysia Ludford und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Colorectal Neoplasms, Neoplasms. Die Arbeit wurde bisher 213-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is not well studied in the neoadjuvant space. METHODS This is a phase II open-label, single-center trial of localized unresectable or high-risk resectable MSI-H/dMMR tumors. Treatment is pembrolizumab 200 mg once every 3 weeks for 6 months followed by surgical resection with an option to continue therapy for 1 year followed by observation. To continue on study, patients are required to have radiographic or clinical benefit. The coprimary end points are safety and pathologic complete response. Key secondary end points are response rate and organ-sparing at one year for patients who declined surgery. Exploratory analyses include interrogation of the tumor immune microenvironment using imaging mass cytometry. RESULTS A total of 35 patients were enrolled, including 27 patients with colorectal cancer and eight patients with noncolorectal cancer. Among 33 evaluable patients, best overall response rate was 82%. Among 17 (49%) patients who underwent surgery, the pathologic complete response rate was 65%. Ten patients elected to receive one year of pembrolizumab followed by surveillance without surgical resection (median follow-up of 23 weeks [range, 0-54 weeks]). An additional eight did not undergo surgical resection and received less than 1 year of pembrolizumab. During the study course of the trial and subsequent follow-up, progression events were seen in six patients (four of whom underwent salvage surgery). There were no new safety signals. Spatial immune profiling with imaging mass cytometry noted a significantly closer proximity between granulocytic cells and cytotoxic T cells in patients with progressive events compared with those without progression. CONCLUSION Neoadjuvant pembrolizumab in dMMR/MSI-H cancers is safe and resulted in high rates of pathologic, radiographic, and endoscopic response, which has implications for organ-sparing strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalColorectal NeoplasmsNeoplasmsHumansDNA Mismatch RepairMicrosatellite InstabilityNeoadjuvant TherapyTumor MicroenvironmentAntibodies, Monoclonal, Humanized

Substanzen

Antineoplastic Agents, ImmunologicalpembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Gastrointestinal Medical Oncology, The University of Texas. MD Anderson Cancer Center, Houston, TX.
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
  • Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Kaysia Ludford, Won Jin Ho, Jane V Thomas, Kanwal P S Raghav, Mariela Blum Murphy, Nicole D Fleming, Michael S Lee, Y Nancy You, Eduardo Vilar, Arvind Dasari, Sarah Shin, Alexei Hernandez, Xuan Yuan, Wai Chin Foo, Wei Qiao, Dipen Maru, Scott Kopetz, Michael J Overman

Förderung

  • NCI NIH HHS

Zitieren

APA

Ludford, K., Ho, W. J., Thomas, J. V., Raghav, K. P. S., Murphy, M. B., Fleming, N. D., Lee, M. S., Smaglo, B. G., You, Y. N., Tillman, M. M., Kamiya-Matsuoka, C., Thirumurthi, S., Messick, C., Johnson, B., Vilar, E., Dasari, A., Shin, S., Hernandez, A., Yuan, X., …, & Overman, M. J. (2023). Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. Journal of Clinical Oncology, 41(12), 2181-2190. https://doi.org/10.1200/jco.22.01351

Vancouver

Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, et al. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. Journal of Clinical Oncology. 2023;41(12):2181-2190. doi:10.1200/jco.22.01351

BibTeX
@article{Ludford2023,
  author = {Ludford, Kaysia and Ho, Won Jin and Thomas, Jane V and Raghav, Kanwal P S and Murphy, Mariela Blum and Fleming, Nicole D and Lee, Michael S and Smaglo, Brandon G and You, Y Nancy and Tillman, Matthew M and Kamiya-Matsuoka, Carlos and Thirumurthi, Selvi and Messick, Craig and Johnson, Benny and Vilar, Eduardo and Dasari, Arvind and Shin, Sarah and Hernandez, Alexei and Yuan, Xuan and Yang, Hongqui and Foo, Wai Chin and Qiao, Wei and Maru, Dipen and Kopetz, Scott and Overman, Michael J},
  title = {Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {12},
  pages = {2181--2190},
  doi = {10.1200/jco.22.01351}
}
Kostenlos starten →